UDCA and 18β-GA alleviate ethinylestradiol-induced cholestasis via downregulating RORγt and CXCR3 signaling pathway in iNKT cells.

[1]  Sihan Sheng,et al.  Dihydroartemisinin-ursodeoxycholic acid conjugate is a potential treatment agent for inflammatory bowel disease. , 2023, International immunopharmacology.

[2]  Luyong Zhang,et al.  iNKT17 cells play a pathogenic role in ethinylestradiol-induced cholestatic hepatotoxicity , 2022, Archives of Toxicology.

[3]  L. Tao,et al.  Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. , 2022, Biochimica et biophysica acta. Molecular basis of disease.

[4]  Xinzhi Wang,et al.  Activation of natural killer T cells contributes to Th1 bias in the murine liver after 14 d of ethinylestradiol exposure , 2022, World journal of gastroenterology.

[5]  Hetong Zhou,et al.  IL‐17A produced by invariant natural killer T cells and CD3+CD56+αGalcer‐CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis , 2022, Journal of leukocyte biology.

[6]  Daeui Park,et al.  Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction through changing macrophage polarization. , 2022, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  A. Edelman,et al.  Contraception Selection, Effectiveness, and Adverse Effects: A Review. , 2021, JAMA.

[8]  Jianxia Wen,et al.  Comparative Evidence for Intrahepatic Cholestasis of Pregnancy Treatment With Traditional Chinese Medicine Therapy: A Network Meta-Analysis , 2021, Frontiers in Pharmacology.

[9]  Jin-yu Yang,et al.  The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives , 2021, Frontiers in Pharmacology.

[10]  A. Theiss,et al.  RORγt protein modifications and IL-17-mediated inflammation. , 2021, Trends in immunology.

[11]  J. Hippisley-Cox,et al.  Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases , 2021, BMJ.

[12]  T. Simoncini,et al.  Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. , 2021, Human reproduction update.

[13]  A. Nakajima,et al.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents , 2021, Drugs.

[14]  M. Ávila,et al.  Fibrotic Events in the Progression of Cholestatic Liver Disease , 2021, Cells.

[15]  S. Kane,et al.  Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis , 2021, The lancet. Gastroenterology & hepatology.

[16]  J. Manson,et al.  Recommended Hormone Therapy in Menopause: Concepts, Controversies and Approach to Treatment. , 2021, Endocrine reviews.

[17]  J. Fleckenstein,et al.  Intrahepatic Cholestasis of Pregnancy: Natural History and Current Management , 2021, Seminars in Liver Disease.

[18]  Richard H. Lee,et al.  Society for Maternal-Fetal Medicine (SMFM) Consult Series #53: Intrahepatic Cholestasis of Pregnancy. , 2020, American journal of obstetrics and gynecology.

[19]  R. Dhiman,et al.  Role of ursodeoxycholic acid on maternal serum bile acids and perinatal outcomes in intrahepatic cholestasis of pregnancy. , 2020, European journal of gastroenterology & hepatology.

[20]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases , 2020, BMJ.

[21]  Lixin Sun,et al.  The role of invariant natural killer T cells and associated immunoregulatory factors in triptolide-induced cholestatic liver injury. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[22]  P. Middleton,et al.  Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. , 2020, The Cochrane database of systematic reviews.

[23]  A. Montano‐Loza,et al.  Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Li-kun Gong,et al.  Research progress on the protective effects of licorice-derived 18β-glycyrrhetinic acid against liver injury , 2020, Acta Pharmacologica Sinica.

[25]  K. Kowdley,et al.  Primary Sclerosing Cholangitis: Epidemiology, Genetics, Diagnosis, and Current Management , 2020, Clinical liver disease.

[26]  E. Hadar,et al.  Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia , 2020, Archives of Gynecology and Obstetrics.

[27]  G. Hirschfield,et al.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities , 2019, Nature Reviews Gastroenterology & Hepatology.

[28]  Shengjia Zhao,et al.  An "essential herbal medicine"-licorice: A review of phytochemicals and its effects in combination preparations. , 2019, Journal of ethnopharmacology.

[29]  Jennifer L. Bell,et al.  Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial , 2019, The Lancet.

[30]  P. Watkins,et al.  Drug-induced liver injury , 2019, Nature Reviews Disease Primers.

[31]  J. Hotaling,et al.  The History of Estrogen Therapy. , 2019, Sexual medicine reviews.

[32]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[33]  S. Olafsson,et al.  Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study , 2019, Scandinavian journal of gastroenterology.

[34]  Ageliki Tsagaratou.  Unveiling the regulation of NKT17 cell differentiation and function , 2019, Molecular immunology.

[35]  T. Berg,et al.  Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients , 2018, PloS one.

[36]  M. Fischbach,et al.  Bile acid metabolites control Th17 and Treg cell differentiation , 2018, bioRxiv.

[37]  G. Prins,et al.  Estrogens and prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.

[38]  Guo-zhen Xing,et al.  18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway , 2018, Acta Pharmacologica Sinica.

[39]  Dandan Shi,et al.  Celastrol Attenuates Intrahepatic Cholestasis of Pregnancy by Inhibiting Matrix Metalloproteinases-2 and 9. , 2018, Annals of hepatology.

[40]  M. Kronenberg,et al.  Tissue-specific functions of invariant natural killer T cells , 2018, Nature Reviews Immunology.

[41]  L. Reis,et al.  Estrogen therapy in patients with prostate cancer: a contemporary systematic review , 2018, International Urology and Nephrology.

[42]  R. Chapman,et al.  NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid , 2018, Hepatology communications.

[43]  K. Lindor,et al.  Complications, symptoms, quality of life and pregnancy in cholestatic liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[44]  W. Liu,et al.  Glycyrrhetic Acid Derivative TY501 Protects Against Lithocholic Acid–Induced Cholestasis , 2017, Drug Research.

[45]  Min-jung Park,et al.  Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE. , 2017, Immunology letters.

[46]  F. Gonzalez,et al.  Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. , 2017, Toxicology.

[47]  G. Minuk,et al.  Diagnostic considerations for cholestatic liver disease , 2017, Journal of gastroenterology and hepatology.

[48]  Ji-Eun Lee,et al.  18β-Glycyrrhetinic acid, the major bioactive component of Glycyrrhizae Radix, attenuates airway inflammation by modulating Th2 cytokines, GATA-3, STAT6, and Foxp3 transcription factors in an asthmatic mouse model. , 2017, Environmental toxicology and pharmacology.

[49]  J. Burdette,et al.  Phytosteroids beyond estrogens: Regulators of reproductive and endocrine function in natural products , 2017, Molecular and Cellular Endocrinology.

[50]  A. S. Zepeda-Morales,et al.  Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression. , 2016, Annals of hepatology.

[51]  Mudan Lu,et al.  Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats. , 2016, Canadian journal of physiology and pharmacology.

[52]  Y. Chawla,et al.  A molecular marker of disease activity in autoimmune liver diseases with histopathological correlation; FoXp3/RORγt ratio , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[53]  Hyunyoung Jeong,et al.  Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice , 2015, Molecular Pharmacology.

[54]  Mathias Dunkel,et al.  SuperPred: update on drug classification and target prediction , 2014, Nucleic Acids Res..

[55]  Yoshinobu Sato,et al.  Increased activated natural killer T cells in the liver of patients with advanced stage primary biliary cirrhosis. , 2014, Biomedical research.

[56]  Hyung Keun Kim,et al.  18β-Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses , 2013, Immunopharmacology and immunotoxicology.

[57]  Wenxiu Zhao,et al.  18β‐glycyrrhetinic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell‐mediated immunosuppression in mice , 2013, International journal of cancer.

[58]  G. Kolios,et al.  CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid , 2013, Clinical and experimental immunology.

[59]  B. Liu,et al.  The Role of CXCR3 in the Induction of Primary Biliary Cirrhosis , 2011, Clinical & developmental immunology.

[60]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[61]  Chaoming Mao,et al.  18β-Glycyrrhetinic Acid Ameliorates Acute Propionibacterium acnes-induced Liver Injury through Inhibition of Macrophage Inflammatory Protein-1α* , 2009, The Journal of Biological Chemistry.

[62]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[63]  M. Arrese,et al.  UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. , 2019, Handbook of experimental pharmacology.

[64]  F. Limongi.  Th1 cytokines and chemokines in primary biliary cirrhosis. , 2015, La Clinica terapeutica.

[65]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.